Is Global Health overvalued or undervalued?

As of 13 November 2025, the valuation grade for Global Health has moved from expensive to very expensive. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 53.84, an EV to EBITDA of 33.35, and a Price to Book Value of 9.53. These figures suggest that the stock is trading at a significant premium compared to its earnings and book value. In comparison with peers, Global Health's PE ratio is lower than that of Max Healthcare, which stands at 88.67, but higher than Apollo Hospitals at 64.07. Additionally, the PEG ratio of Global Health is 2.37, which indicates a higher growth expectation relative to its earnings compared to Narayana Hrudaya, which has a PEG of 0.00. Despite a positive year-to-date return of 10.9% compared to the Sensex's 8.11%, the overall valuation metrics suggest that Global Health is overvalued in the current market environment.